Abstract | BACKGROUND: METHODS: Multicenter, randomized, controlled, double-blind study, with COPD or OHS patients with MV < 72 h and initial bicarbonate >28 mmol/L and pH > 7.35. Test-treatment, ACTZ 500 mg or placebo, was daily administered if pH > 7.35 and bicarbonate >26 mmol/L. Clinical, respiratory and laboratory parameters were recorded. RESULTS: 47 patients (36 men) were randomized. There were no significant differences between groups in comorbidities, baseline characteristics or arterial blood gases at inclusion. The mean difference in the duration of MV between placebo and ACTZ group was 1.3 days (95%CI, -2.1-4.8; p = 0.44). Kaplan-Meier curves showed no differences in the duration of MV (Log-Rank p = 0.41). Between-group comparison of estimated marginal means (CI 95%) during MV were, respectively: PaCO2 55 (51-59) vs 48 (47-50) mm Hg, p = 0.002; bicarbonate concentration 34 (32-35) vs 29 (28-30) mmol/L, p < 0.0001; and minute volume 9.7 (8.9-10.4) vs 10.6 (9.2-12.0) L/min, p = 0.26. There were no severe adverse effects with ACTZ administration. CONCLUSIONS: Among patients with MA and COPD or OHS, early treatment with ACTZ did not shorten significantly the duration of MV compared with placebo. TRIAL REGISTRY: clinical.trials.gov; NCT01499485; URL:.www.clinicaltrials.gov.
|
Authors | G Rialp Cervera, J M Raurich Puigdevall, I Morán Chorro, M C Martín Delgado, G Heras la Calle, A Mas Serra, I Vallverdú Perapoch |
Journal | Pulmonary pharmacology & therapeutics
(Pulm Pharmacol Ther)
Vol. 44
Pg. 30-37
(06 2017)
ISSN: 1522-9629 [Electronic] England |
PMID | 28286047
(Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2017 Elsevier Ltd. All rights reserved. |
Chemical References |
- Bicarbonates
- Acetazolamide
|
Topics |
- Acetazolamide
(administration & dosage)
- Acidosis
(therapy)
- Aged
- Bicarbonates
(blood)
- Blood Gas Analysis
- Double-Blind Method
- Female
- Follow-Up Studies
- Humans
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Obesity Hypoventilation Syndrome
(therapy)
- Pulmonary Disease, Chronic Obstructive
(therapy)
- Respiration, Artificial
(methods)
- Time Factors
|